Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and webcast on July 30, 2020, at 8:00 a.m. ET to discuss its Q2 2020 financial results and other business highlights. Investors can access the live webcast via the company's website under the 'Events & Presentations' section. Agios focuses on developing novel therapies for cancer and rare genetic diseases, boasting two approved oncology medications and a robust pipeline of investigational therapies.
- Agios has two approved oncology precision medicines.
- Active research and discovery pipeline across oncology and rare genetic diseases.
- None.
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 2955575. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.
Contacts
Investors:
Holly Manning, 617-844-6630
Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Associate Director, Corporate Communications
Jessica.Rennekamp@agios.com
FAQ
When will Agios Pharmaceuticals report its Q2 2020 financial results?
How can I access the Agios Pharmaceuticals conference call?
Where can I find more information about Agios Pharmaceuticals' business?
What is the focus of Agios Pharmaceuticals?
